Praxis Precision Medicines (PRAX) Gets a Buy From Piper Sandler
Praxis Precision Medicine Analyst Ratings
Piper Sandler Initiates a Buy Rating on Praxis Precision Medicines (PRAX)
Praxis Precision Medicine Analyst Ratings
Praxis Precision Medicine Analyst Ratings
Analysts' Top Healthcare Picks: Praxis Precision Medicines (PRAX), Corbus Pharmaceuticals (CRBP)
Praxis Precision Medicine Analyst Ratings
Buy Rating Backed by Robust Pipeline and Market Opportunity for Praxis Precision Medicines
Praxis Precision Medicine Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Bluebird Bio (BLUE) and Nuvalent (NUVL)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Theravance Biopharma (TBPH), Voyager Therapeutics (VYGR) and Praxis Precision Medicines (PRAX)
Praxis Precision Medicine Analyst Ratings
Praxis Precision Medicine Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)
Wedbush Trims Price Target on Praxis Precision Medicines to $40 From $41 After $200 Million Secondary Offering, Maintains Neutral Rating
Analysts' Top Healthcare Picks: Praxis Precision Medicines (PRAX), GlycoMimetics (GLYC)
Praxis Precision Medicine Analyst Ratings
Buy Rating Affirmed for Praxis Precision Medicines' PRAX-628 Based on Strong Clinical Trial Outcomes and Market Potential
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Clene (CLNN) and Jazz Pharmaceuticals (JAZZ)
Buy Rating Affirmed for Praxis Precision Medicines Amidst Promising Pipeline and Financial Stability